Friday, 6 November 2026European Markets
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· June 14, 2026

AI spending boom is boosting profits now, but could pressure Big Tech returns later: Goldman Sachs

View original at seekingalpha.com
AI spending boom is boosting profits now, but could pressure Big Tech returns later: Goldman Sachs [Server room] gremlin The artificial intelligence investment boom has helped propel S&P 500 (SP500 [https://seekingalpha.com/symbol/SP500]) profitability to record levels, but Goldman Sachs warns that the same spending wa…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Every one percentage point change in S&P 500 ROE is associated with roughly a one-turn change in the market's P/E multiple

    60% confidence
  • Apple is expected to experience the sharpest ROE drop next year, followed by Nvidia, Alphabet and Meta

    60% confidence
  • The S&P 500 currently trades at about 21 times forward earnings, a level that ranks in the 87th percentile since 1980, while return on equity has climbed to a record 22%

    60% confidence
  • The broader productivity benefits of AI could ultimately offset near-term headwinds from AI infrastructure spending on Big Tech profitability

    60% confidence
  • Economics for AI models are expected to improve as computing costs per token decline while pricing stabilizes

    60% confidence
  • More than half of S&P 500 companies discussed AI-related productivity initiatives during recent earnings calls, though relatively few have yet quantified the financial impact

    60% confidence
  • Semiconductor net profit margins are approaching 50%, supported by pricing power and strong competitive positions

    60% confidence
  • Depreciation and amortization expenses for hyperscalers will rise from 7% of revenue in 2022 to 12% by 2027

    60% confidence
  • Consensus forecasts imply that return on equity for the largest technology companies will decline by an average of seven percentage points next year

    60% confidence
  • The seven largest technology stocks collectively generate a 44% return on equity, up nine percentage points over the past three years

    60% confidence
  • Improving revenue estimates, growing customer backlogs and expanding margins among major cloud providers are evidence that AI investments are beginning to generate returns

    60% confidence
  • AI adoption will eventually increase revenue and earnings per employee across corporate America

    60% confidence
  • The S&P 500 has returned 9% year-to-date despite a decline in valuation multiples, with consensus forward 12-month earnings estimates rising 17% while the P/E ratio contracted from 22x to 21x

    60% confidence
  • Record corporate profitability has become a key pillar supporting elevated U.S. stock valuations

    60% confidence
  • Major cloud operators will spend roughly $770 billion on capital expenditures in 2026, equivalent to about 100% of their operating cash flow

    60% confidence

Data points we hold from this source

S&P 500 Index Fund · margin22 percent_ROE
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Oncology Data Season and Biotech Capital Allocation: ESMO Readouts, Ivonescimab PDUFA, and Diverging Corporate Moves
Late-2026 biotech is driven by a dense catalyst calendar. ESMO 2026 delivers data from ivonescimab, Enhertu, R-DXd and bemarituzumab, and the FDA has set a 14 Nov PDUFA date for the ivonescimab BLA. Capital allocation is diverging. Krystal Biotech authorized a $400M buyback while lowering FY2026 spend guidance and pushing milestones into 2027. Spago is moving to delist from Nasdaq First North. The facts are clinical and corporate events, not AI or fintech, so the finance angle is limited to capital markets (buybacks, guidance, delistings, regulatory timelines).
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,996
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,996 facts checked against source5,552 source documents archived
Query this data → isubstrate.com
AI spending boom is boosting profits now, but could pressure Big Tech returns later: Goldman Sachs — Source | Via News | ViaNews EU